2022 non-GAAP* EPS guidance has been lowered to $10.10-10.35 (vs $10.30-10.80 three months ago and $10.75-11.25 six months ago). The biggest components of the lowered guidance vs three months ago are FX and supply-chain bottlenecks.
*Excludes legal expenses for earplug and PFAS cases. The next trial in the earplug MDL will be in Feb 2023. The next trial in the PFAS MDL will be in Jun 2023.
Market Data 
Markets 
AI
